May 2 (Reuters) - Cortexyme Inc :
* CORTEXYME - CO IS FURTHER REDUCING HEADCOUNT BY 36%, BRINGING TOTAL REDUCTION TO 67% FROM JANUARY 2022 HEADCOUNT LEVELS
* CORTEXYME - MAJORITY OF CURRENT REDUCTION IN FORCE IS EXPECTED TAKE PLACE BY END OF MAY 2022, & REMAINDER IS EXPECTED BE COMPLETED BY END OF JULY 2022
* CORTEXYME - IN CONNECTION WITH CURRENT REDUCTION IN FORCE, CO ESTIMATES THAT IT WILL INCUR EXPENSES OF ABOUT $0.7 MILLION
Source text: [ID: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments